natgillin/translations-raw huggingface dataset:
Building engineering module according to claim 1, characterized in that one or more means for producing energy, such as a solar panel or windmill, is fitted, or can be fitted, to the building engineering module. 
Građevinski modul u skladu s patentnim zahtjevom 1, naznačen time što je u građevinski modul ugrađeno, 1li može biti ugrađeno, jedno ili više sredstava za proizvodnju energije, poput solarne ploče ili vjetrenjače.
An MMVF substrate according to claim 16 or claim 17, wherein the density of the MMVF substrate is in the range 15 to 250 kg/m3, preferably in the range 20 kg/m3 to 180 kg/m3, most in the range preferably 60 kg/m3 to 150 kg/m3. 
MMF supstrat sukladno zahtjevu 16 ili 17, naznačen time, što je gustoća MMVF supstrata u rasponu 15 do 250 kg / m3, poželjno u rasponu od 20 kg/m3 do 180 kg/m3, posebno poželjno u rasponu od 60 kg/m3 do 150 kg/m3.
optionally up to 30% by weight of a pharmaceutically acceptable hydrophilic solvent; or (B) 
opcijski do 30 masenih % farmaceutski prihvatljivog hidrofilnog otapala; ili
A method for combating or controlling invertebrate pests, which method comprises contacting said pest or its food supply, habitat or breeding grounds with a pesticidally effective amount of at least one compound of claim 1 . 
Neterapeutski postupak za borbu protiv ili kontrolu beskičmenjaka štetočina, pri čemu taj postupak sadrži dovođenje u kontakt navedene štetočine ili njegovih zaliha hrane, staništa ili zemljišta na kojem se uzgaja sa pesticidno efikasnom količinom najmanje jednog spoja prema bilo kojem od patentnih zahtjeva 1 do 11.
In an alternative embodiment, and with reference to the magnetic field simulation depicted in FIG. 1 b, the engraving in the permanent-magnetic body may also be filled up with another material. 
U alternativnom utjelovljenju, a vezano uz simulaciju magnetskog polja prikazanu na Slici 1b, gravura u permanentno magnetskom tijelu također se može ispuniti i drugim materijalom.
and wherein the silyl protecting groups are selected from the group consisting of a trimethylsilyl group, a tert-butyldimethylsilyl group, a methyldiisopropylsilyl group, a triisopropylsilyl group, a tetraisopropyldisiloxyl (TIPDS) group and a diphenylmethylsilyl group. 
te time, da su silil-zaštitne skupine odabrane iz skupine koju čine: trimetilsilil-skupina, tert-butildimetilsilil-skupina, metildiizopropilsilil-skupina, triizopropilsilil-skupina, tetraizopropildisiloksil (TIPDS)-skupina i difenilmetilsilil-skupina.
The pharmaceutical composition of claim 54, further comprising a buffer solution. The pharmaceutical composition of claim 57, wherein the buffer solution comprises acetate, citrate, prolamine, carbonate, or phosphate or any combination thereof. 
navedeno RNAi sredstvo se treba primijeniti s otopinom pufera, pri čemu poželjno navedena otopina pufera sadrži acetat, citrat, prolamin, karbonat, ili fosfat ili bilo koju njihovu kombinaciju, te pri čemu je najpoželjnije da navedena puferska otopina je puferirana otopina fosfatnih soli (PBS).
wherein the coupling member comprises a portion which is held by the flap when the flap is in its first position, while the portion of the coupling member is released by a movement of the flap from its first position to its second position. 
HR P20191223T1 (20) ako je u svom prvom položaju, dok se dio (34) elementa (30) za spajanje oslobađa kretanjem zaklopke (20) iz svog prvog položaja u svoj drugi položaj.
These models include but are not limited to mouse or rat collagen-induced arthritis, rat adjuvant-induced arthritis, and collagen antibody-induced arthritis. Autoimmune diseases including, but not limited to, multiple sclerosis, type I-diabetes mellitus, uveoretinitis, thyroditis, myasthenia gravis, immunoglobulin nephropathies, myocarditis, airway sensitization (asthma), lupus, or colitis may also be used to evaluate the therapeutic potential of compounds herein. 
Spoj ili sol za upotrebu prema zahtjevu 22, naznačen time da a) navedena autoimuna bolest predstavlja poremećaj na koži, multiplu sklerozu, reumatoidni artritis, psorijazni artritis, juvenilni artritis, dijabetes tip I, lupus, upalnu bolest crijeva, Crohnovu bolest, mijasteniju gravis, imunoglobulinsku nefropatiju, miokarditis, ili autoimuni poremećaj štitnjače; ili b) navedena autoimuna bolest predstavlja reumatoidni artritis; ili
The method of claim 1, 4-5, and 7 wherein the formation systems are pulsed power formation systems. 
Postupak prema zahtjevu 1, 4 do 5 i 7, naznačen time, da su tvorbeni sustavi impulsni strujni tvorbeni sustavi.
Use according to claim 12, characterised in that the pain is selected from inflammatory pain, neuropathic pain, acute pain, chronic pain, visceral pain, migraine pain and cancer pain. 
Uporaba prema zahtjevu 10, naznačena time što je bol odabrana od upalne boli, neuropatske boli, akutne boli, kronične boli, visceralne boli, migrenske boli i boli od raka.
The antibody or functional protein according to any of enbodiments 1-7, wherein said antibody comprises a heavy chain variable region CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-14; a heavy chain variable region CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 15-28; a heavy chain variable region CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 29-42; a light chain variable region CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 43-56; a light chain variable region CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 57-70; and a light chain variable region CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 71-84. 
CDR2 varijabilnog područja jakog lanca, koje sadrži aminokiselinsku sekvencu odabranu iz skupine koju čine SEQ ID Nos: 18-28; CDR3 varijabilnog područja jakog lanca, koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 37; CDRI varijabilnog područja slabog lanca, koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 51; CDR2 varijabilnog područja slabog lanca, koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 65; i CDR3 varijabilnog područja slabog lanca, koje sadrži aminokiselinsku sekvencu odabranu iz skupine koju čine SEQ ID Nos: 71-79.
This data showed that 30.2% of patients treated with the highest dose of SR-141716 stayed abstinent from cigarette smoke relative to 14.8% for placebo. 
Ovi podaci su pokazali da je 30.2% pacijenata liječenih sa najvišim dozama SR-1417 6 apstiniralo od cigareta u usporedbi sa 14.8% za placebo.
The use of microcapsules with a polymeric wall according a suitable combination of claims 1 to 29 or produced according a suitable combination of claims 30 to 40 in an agrochemical formulation characterized in that the microencapsulated material is trifluthrin and/or phenothrin. 
Mikrokapsule prema pogodnoj kombinaciji patentnih zahtjeva 1 do 27, naznačene time, što je mikroinkapsulirani materijal triflutrin i/ili fenotrin.
C2-7 alkenyl containing 1-3 double bonds, or monocyclic, bicyclic or tricyclic aryl optionally substituted with one or more C1-6 alkoxy, trifluoro-C1-6 alkoxy, C1-6-alkoxycarbonil, C1-6alkanoyl, aryl, C1-6 alkylthio, halogen or cyano, or 
C22 alkenil koji sadrži 1-3 dvostruke veze, ili monociklički, biciklički ili triciklički aril opcijski zamijenjen sa jednom ili više C;.4-alkoksijem, trifluoro-C,.galkoksijem, Ci.g-alkoksikarbonilom, C;.g-alkanoilom, arilom, C; g-alkiltiom, halogenom ili cijanom, ili opcijski zamijenjen sa monocikličkom, bicikličkom ili tricikličkom C3_14-cikloalkilnom skupinom, ili tolilnom skupinom, ili
The method of embodiment 655, wherein said exposure to a basic pH is performed at a temperature of 26°C. 
(1i) izloženost lužnatoj pH se izvodi na temperaturi od 22*C do 28*C ili temperaturi od 26C; i/ili
reacting the alcohol B with methanesulfonic anhydride or methanesulfonyl chloride in presence of a base to give (S) neopentyl 3-(benzyloxycarbonylamino) 4-(methylsulfonyloxy)butane 1-sulfonate C; 
(b) reagiranje alkohola B s metansulfonskim anhidridom ili metansulfonskim kloridom u prisutnosti baze kako bi se dobio (S) neopentil 3-(benziloksikarbonilamino) 4-(metilsulfoniloksi)butan 1-sulfonat €;
VL1-L1-VL2-L2-CL [I] and two polypeptide chains have a structure represented by the formula: 
VL-Lr-VLe-D-CL [1] i dva polipeptidna lanca imaju strukturu predstavljenu s formulom:
a processor; a memory coupled with the processor; a first software module executable by the processor and the memory, the first software module configured to identify (100) an invalid field of a portable executable file by comparing attributes of the fields of said portable executable file to valid characteristics of valid corresponding fields as specified in the portable executable file format specification; 
Sustav koji sadrži: procesor; memoriju spojenu sa procesorom; prvi softverski modul izvršiv putem procesora i memorije, prvi softverski modul konfiguriran da identificira (100) nevažećeg polje prijenosne izvršne datoteke uspoređivanjem atributa polja spomenute prijenosne izvršne datoteke sa važećim karakteristikama važećih odgovarajućih polja kako je navedeno u specifikacijama formata prijenosne izvršne datoteke; drugi softverski modul izvršiv putem procesora i memorije, drugi softverski modul konfiguriran da odredi (102) vjerojatnost popravka nevažećeg polja prijenosne izvršne datoteke utvrđujući (114) broj i karakteristike
compressed rolls (1a, 1b, 1c, 1d, 2a, 2b, 2c, 2d) of mineral wool which are individually packaged within a plastic film or compressed stacks of mineral wool panels (22a, 22b, 22c, 22d, 22e, 22f, 22g, 22h) which are packed in a plastic film (3) to form a package of panels, wherein 
- - stlačene valjke (Ia, Ib, Ic, Id, 2a, 2b, 2c, 2d) mineralne vune koji su pojedinačno pakirani u plastičnoj foliji ili stlačene stogove ploča od mineralne vune (224, 22b, 22c, 22d, 22e, 22f, 22g, 22h) koji su pakirani u plastičnoj foliji (3) i čine paket ploča, pri čemu
The method of claim 20, wherein the compound or salt is administered in a composition comprising at least one pharmaceutically acceptable carrier, excipient, or diluent. The method of claim 20, wherein the patient suffers from a condition selected from the group consisting of rheumatoid arthritis, gouty arthritis, osteoarthritis, rachitis, systemic lupus erythematosus, psoriasis, eczema, dermatitis, postpartum inflammation, gastritis, irritable bowel syndrome, headache, exarteritis, thyroiditis, aplastic anemia, retinitis, conjunctivitis, retinopathy, uveitis, hemeralopia, acute ocular tissue injury, cystic fibrosis, allergic rhinitis, coronary plaque inflammation, ocular vascular hyperplasia, retinal vascular hyperplasia, and gastric ulcer. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema bilo kojem od prethodno navedenih patentnih zahtjeva za upotrebu u liječenju inflamacije naznačene reumatoidnim artritisom, gihtom, osteoartritisom i rahitisom, ili podrazumjeva jedan sistemski eritemski lupus, psorijazu, ekcem, inflamaciju kože i postpartalnu inflamaciju, bolesti crijeva, gastritis, sindrom iritabilnog crijeva, glavobolju, periarteritis, tiroiditis, aplastičnu anemiju, retinitis, konjuktivitis, retinopatije, uveitis, hemeralopiju, akutnu očnu povredu tkiva, virusne infekcije i cistične fibroze, alergijski rinitis, postpartalni bol, zubobolju, mišićinu bol, bol uslijed kancerogenog oboljenja, aneurizmu, koronarnu plak inflamaciju, inflamaciju uzrokovanu bakterijama, inflamaciju uzrokovanu virusima, inflamaciju uzrokovanu kirurški, okularnu vaskularnu hiperplaziju, retinalnu vaskularnu hiperplaziju i peptički ulkus.
A glycosylated human Serum Amyloid P (SAP) polypeptide for use in inhibiting the differentiation of monocytes into fibrocytes, wherein the SAP polypeptide comprises an N-linked oligosaccharide chain, and wherein at least one branch of the oligosaccharide chain terminates with a a2,3-linked sialic acid moiety. 
Glikozilirani humani serumski amiloidni P (SAP) polipeptid za upotrebu u inhibiranju diferencijacije monocita u fibrocite, naznačen time, da SAP polipeptid sadržava N-vezani oligosaharidni lanac i pri čemu barem jedna grana oligosaharidnog lanca završava s a2,3- vezanim ostatkom sijalične kiseline.
fractional atomic coordinates substantially as listed in Table 1 at a temperature of about 25 °C, Table 1 
frakcijske atomske koordinate, na temperaturi od oko 25 °C, koje su u biti navedene u Tabeli 1:
In a preferred embodiment of the pharmaceutical composition according to the present invention, the ratio by weight of peptides to mannitol to poloxamer 188 is in the range including and between 1:0:2 to 1:0:2.2. 
Farmaceutski sastav prema zahtjevu 1, naznačeno time da je maseni udio peptida naspram manitola i poloksamera 188 u rasponu od 1:0:2 do 1:0:2,2.
any line from edge to edge or corner to corner of the respective injector mold plate (2) or ejector mold plate (3). 
bilo koje linije od ruba do ruba ili od kuta do kuta odgovarajuće ploče kalupa za injektiranje (2) ili ploče kalupa za izbacivanje(3)
For use, the contents of the vial are mixed with 2 mL of physiological saline, to produce an injectable preparation. 
Za primjenu, sadržaj epruvete je miješan sa 2 ml fiziološke otopine, da bi se proizveo injektabilni preparat,
Electroshock in Mice [Svirinyard et al., J. Pharmacol. 
Elektrošokovi kod miševa [Swinyard i sur.., J. Pharmacol.
cooling the pasteurized mixture to 4 to 6 °C 
hlađenje pasterizirane smjese na 4 do 6 °C,
supplying the remainder of the pre-fuel composition comprising methanol and water to a second tank that is in fluid connection to a combustion chamber of the compression ignition engine. 
- < snabdjevanje ostatka smjese predgoriva koja sadrži metanol i vodu do drugog spremnika koji je u tekućem spoju s komorom za sagorjevanje motora s kompresijskim paljenjem.
The method of claim 2, wherein the polar aprotic solvent is selected from acetonitrile, dimethyl sulfoxide, hexamethylphosphoramide, dimethylformamide, (dimethylacetamide), and N-methylpyrrolidone. 
Postupak prema bilo kojem od zahtjeva 1, 2 i 3, pri čemu je aprotonsko otapalo izabrano iz grupe koja se sastoji od acetonitrila, dimetilsulfoksida, dimetilformamida, kloroforma, diklorometana i njihovih kombinacija.
A pharmaceutical composition comprising a pharmaceutically acceptable excipient or pharmaceutically acceptable carrier and a fusion protein dimer of claim 1 or claim 2. 
Farmaceutski pripravak naznačen time da sadrži farmaceutski prihvatljivu pomoćnu tvar ili farmaceutski prihvatljiv nosač i jedno ili više od slijedećeg:
In another embodiment the method comprises applying from about 20-700 ug of a compound according to Formula I from 1 to 2 times daily. 
(li) od otprilike 20 do otprilike 700 ug tvari od 1 do 2 puta na dan, ili
A pharmaceutical composition according to claim 16, wherein the total of high and low molecular weight PEO comprises at least about 80% (by weight) of the dosage form. 
Oblik doziranja s produljenim otpuštanjem prema zahtjevima od 1 do 11, naznačen time da sastojak sadrži barem oko 80 % (po težini) polietilen oksida.
The composition of claim 1 or claim 2, wherein the digestive enzymes are in the form of enterically coated pancrelipase beads. 
Kompozicija u skladu sa zahtjevom 1 ili zahtjevom 2, naznačena time što su digestivni enzimi u formi enterički obloženih zrna pankrelipaze.
In some embodiments, the disease or condition is selected from the group consisting of: an autoimmune disease, inflammatory disease, an allergy, transplantation rejection, and a hyperimmune response. 
Spoj za uporabu sukladno zahtjevu 10, pri čemu je navedena bolest ili stanje autoimuna bolest, upalna bolest, alergija, odbacivanje transplantacije ili hiperimuni odgovor.
and R21 are independently hydrogen, C1-C3 alkyl, or a group selected from the group consisting of: 
R;1, andR,, su neovisno skupina odabran iz skupine koju čine: 9 o
System and method for assessment of smoking articles 
SUSTAV I POSTUPAK ZA PROCJENU ARTIKALA ZA PUŠENJE
It is to be understood that in one embodiment thereof, 11 dosage units are administered continuously once weekly during a period of 11 weeks followed by one week of no administration of a dosage unit or administration of a placebo. 
Komplet prema zahtjevu 1, naznačen time da je komplet namijenjen za razdoblje liječenja od 12 tjedana i komplet sadrži 11 jediničnih doza koje se daju neprekidno jednom tjedno tijekom razdoblja od 11 tjedana nakon čega slijedi tjedan dana bez davanja jedinica doziranja ili davanje placeba.
The modified IgG4 Fc fragment of claim 1 or 2, wherein the hinge region was mutated by the deletion of 1 to 8 continuous or discontinuous amino acid(s) comprising a Cys residue at the 11th position. 
Modificirani IgG4 Fc fragment prema zahtjevu 1, naznačeno time da je zglobna regija mutirana putem brisanja od 1 do 5 uzastopne/ih ili neuzastopne/ih aminokiselina sadržeći Cis ostatak na osmom položaju.
As a result, the compositions and in particular the second layer are very resistant to mechanical stress and show a self-repair mechanism, particularly when a particle coated with this second layer is introduced into an aqueous medium. 
Zbog toga su pripravci, a osobito drugi sloj u njima, vrlo otporni na mehaničko naprezanje, te pokazuju mehanizam samopopravka, osobito kada čestica obložena tim drugim slojem dospijeva u vodeni medij.
The compound for use according to claim 16, wherein said second active agent is selected from the group consisting of a DNA-hypomethylating agent, a therapeutic antibody that specifically binds to a cancer antigen, a hematopoietic growth factor, a cytokine, an antibiotic, a cox-2 inhibitor, an immunomodulatory agent, an anti-thymocyte globulin, an immunosuppressive agent, and a corticosteroid or a pharmacological derivative thereof or wherein said second active agent is an anti-PDl antibody or an anti-PDL1 antibody. 
Spoj za uporabu u skladu s patentnim zahtjevom 14, pri čemu je navedena druga aktivna tvar izabrana iz grupe koja sadrži DNK-hipometilativnu tvar, terapeutsko antitijelo koje se posebno veže za antigen raka, hematopoetski faktor rasta, citokin, antibiotik, cox-2 inhibitor, imunomodulator, antitimocitni globulin, imunosupresiv i kortikosteroid ili njegov farmakološki derivat ili pri čemu je navedena druga aktivna tvar anti-PDI antitijelo ili anti-PDLI antijelo.
The method of claim 1 or 2, wherein the cleavage half-domains are naturally or non-naturally occurring. 
Postupak prema zahtjevu 1 ili 2, naznačen time, da se poludomene cijepanja pojavljuju prirodno ili neprirodno.
Suitable reaction conditions would be apparent to the skilled person and/or from the literature. 
Prikladni reakcijski uvjeti biti će očiti stručnjaku ili se mogu pronaći u literaturi.
Phase L/b6) The node n draws Erich(if)n from the utility grid by means of the node x; 
* - FazaL/b6) čvorn povlači Frich(1f), iz komunalne mreže putem čvora x; .
providing a second solution; 
pripremanje druge otopine;
The pharmaceutical composition of any of claims 1-4, wherein the composition exhibits an in vitro dissolution profile such that after 2 hours, from about 0% to about 30% by weight of tapentadol is released, after 4 hours, from about 5% to about 22% by weight of tapentadol is released, after 6 hours, from about 15% to about 30% by weight of tapentadol is released, and after 8 hours more than about 40% by weight of tapentadol is released; when measured using USP Basket Method at 75 rpm in 900 ml 0.1 N HCl at 37°C. 
Farmaceutski pripravak prema bilo kojem od zahtjeva 1-5, gdje pripravak pokazuje in vitro disolucijski profil takav da nakon 2 sata, otpušta se od oko 0% do oko 30% po masi tapentadola, nakon 4 sata, otpušta se od oko 5% do oko 22% po masi tapentadola, nakon 6 sati, otpušta se oko 15% do oko 30% po masi tapentadola, te nakon 8 sati se otpušta više od oko 40% po masi tapentadola; mjereno USP Basket postupkom pri 75 rpm u 900 mL 0.1 N HCl pri 37 °C.
For example, the at least one key combination element may include a pair of resilient arms extending from a common base which is pivotally mounted in an arcuate cutout extending from the recess, wherein the recess is formed with grooves radially emanating from the arcuate cutout, and wherein walls of the grooves define limits of angular motion of the resilient arms. 
Npr. barem jedan clement kombinacije ključa može uključivati par pomičnih krakova koji se pružaju iz zajedničke baze koja je ugrađena, tako da se može okretati, u izrez u obliku luka pokraj šupljine, pri čemu šupljina ima utore koji se pružaju radijalno iz tog izreza u obliku luka i gdje stijenke utora određuju granice kuta pokretanja pomičnih krakova.
(b10) an antigen-binding site comprising an H chain CDR 1, 2, and 3 having at least 70% sequence identity with amino acid sequences of SEQ ID NOs: 135, 136, and 137, respectively; and (b11) an antigen-binding site comprising an H chain CDR 1, 2, and 3 having at least 70% sequence identity with amino acid sequences of SEQ ID NOs: 174, 175, and 176, respectively; or 
(b10) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence H-lanca CDR-područja 1, 2 i 3 od SEQ ID NO: 135, 136 odnosno 137 (H-lanac CDR-područja od J346); i (b11) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence H-lanca CDR-područja 1, 2 i 3 od SEQ ID NO: 174, 175 odnosno 176 (H-lanac CDR-područja od J142); ili
A silicone fouling release top coat applied to and over the intermediate silicone tie coat (iv), and optionally A removable polymeric film. 
silikonski vršni premaz za otpuštanje obraštaja, koji sadrži vulkanizabilni silikon i silikonsko ulje, kojeg se primjenjuje na i preko silikonskog vežućeg međupremaza (iv), te izborno
A composition according to claim 1, wherein the one or more monohydric C1-C6 alcohols comprises alcohols selected from the group consisting of primary, secondary, and tertiary aliphatic alcohols. 
Smjesa prema zahtjevu 1 ili 2, gdje sustav primjene sadrži alkohole izabrane iz skupine koja obuhvaća primarne, sekundarne i tercijarne alifatske alkohole.
The artificial T cell receptor of any one of items 14 to 31 which comprises the amino acid sequence according to SEQ ID NO: 46 or a fragment thereof, or a variant of said amino acid sequence or fragment. 
Umjetni T stanični receptor sukladno bilo kojem od patentnih zahtjeva 6 do 10, koji sadrži aminokiselinsku sekvencu sukladno SEK ID BR: 46.
In another aspect is a pharmaceutical composition comprising a compound of Formula (I) and Formula (II) or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug and a pharmaceutically acceptable carrier, excipient, binder or diluent thereof. 
Farmaceutski pripravak koji sadrži spoj prema zahtjevu 1 formule F a" ili njegovu farmaceutski prihvatljivu sol ili farmaceutski prihvatljiv solvat 1 farmaceutski prihvatljiv nosač, ekscipijens, vezivno sredstvo ili otapalo.
The method according to any one of the preceding claims, wherein the number of oil droplets having a size of > 1.2 µm in the second emulsion is 5 x 1010 /ml or less. 
Postupak prema bilo kojem od zahtjeva 6 do 17, naznačen time da je broj kapljica ulja veličine > 1.2 um u drugoj emulziji 5 x 10/! /mlili manji.
The microfluidic device of claim 1, wherein said nanostructured metal oxide is constituted by nanoparticles with a size distribution covering the range from about 2 to about 50 nm and centered within 5 and 15 nm. 
Mikrofluidni uređaj prema zahtjevu 1, gdje je nano-strukturirani metalni oksid sastavljen od nanočestica s raspodjelom veličine koja obuhvaća raspon od oko 2 do oko 50 nm, sa središnjim dijelom raspona unutar 5 1 15 nm.